In vitro expression of receptor activator of nuclear factor-κB ligand and osteoprotegerin in cultured equine articular cells

American Journal of Veterinary Research

Volumn 71, Issue 6, 2010, Pages 615-622

  Byron, Christopher R ^a,b   Barger, Anne M ^a   Stewart, Allison A ^a   Pondenis, Holly C ^a   Fan, Timothy M ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b Ruffian Equine Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; LIPOPOLYSACCHARIDE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECOMBINANT INTERLEUKIN 1BETA;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; HORSE; IMMUNOCYTOCHEMISTRY; METACARPOPHALANGEAL JOINT; METATARSOPHALANGEAL JOINT; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; SYNOVIOCYTE; SYNOVIUM; WESTERN BLOTTING; ANIMAL; ANIMAL DISEASE; BIOSYNTHESIS; CULTURE TECHNIQUE; CYTOLOGY; IMMUNOHISTOCHEMISTRY; JOINT; METABOLISM;

EQUIDAE;

ANIMALS; BLOTTING, WESTERN; CARTILAGE, ARTICULAR; CELL CULTURE TECHNIQUES; CHONDROCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HORSES; IMMUNOHISTOCHEMISTRY; JOINTS; OSTEOPROTEGERIN; RANK LIGAND; SYNOVIAL MEMBRANE;

EID: 77954051131     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.71.6.615     Document Type: Article

References (45)

1. Jeffcott LB, Rossdale PD, Freestone J, et al. An assessment of wastage in Thoroughbred racing from conception to 4 years of age. Equine Vet J 1982;14:185-198.
2. Rossdale PD, Hopes R, Digby NJ, et al. Epidemiological study of wastage among racehorses 1982 and 1983. Vet Rec 1985;116:66-69.
3. Pool RR. Pathologic manifestations of joint disease in the athletic horse. In: McIlwraith CW, Trotter GW, eds. Joint disease in the horse. Philadelphia: WB Saunders Co, 1996;87-104.
4. Morton AJ. Diagnosis and treatment of septic arthritis. Vet Clin North Am Equine Pract 2005;21:627-649.
5. von Rechenberg B, Guenther H, McIlwraith CW, et al. Fibrous tissue of subchondral cystic lesions in horses produce local mediators and neutral metalloproteinases and cause bone resorption in vitro. Vet Surg 2000;29:420-429.
6. Takayanagi H. Inflammatory bone destruction and osteoimmunology. J Periodontal Res 2005;40:287-293.
7. Neumann E, Gay S, Müller-Ladner U. The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. Arthritis Rheum 2005;52:2960-2967.
8. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
9. Wei X, Zhang X, Zuscik MJ, et al. Fibroblasts express RANKL and support osteoclastogenesis in a COX-2-dependent manner after stimulation with titanium particles. J Bone Miner Res 2005;20:1136-1148.
10. Nakashima T, Wada T, Penninger JM. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 2003;15:280-287.
11. Bezerra MC, Carvalho JF, Prokopowitsch AS, et al. RANK, RANKL and osteoprotegerin in arthritic bone loss. Braz J Med Biol Res 2005;38:161-170.
12. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-κB ligand/osteoprotegerin balance. J Immunol 2003;170:2655-2662.
13. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesisinhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998;95:3597-3602.
14. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-357. (Pubitemid 30649812)
15. Nakashima T, Kobayashi Y, Yamasaki S, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-κB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000;275:768-775.
16. Suda K, Udagawa N, Sato N, et al. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide- induced osteoclast formation. J Immunol 2004;172:2504-2510.
17. Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 2002;30:340-346.
18. Skoumal M, Kolarz G, Haberhauer G, et al. Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int 2005;26:63-69.
19. Pulsatelli L, Dolzani P, Silvestri T, et al. Soluble receptor activator of nuclear factor-κB ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases. Biogerontology 2004;5:119-127.
20. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-309.
21. Campagnuolo G, Bolon B, Feige U. Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum 2002;46:1926-1936.
22. Kadri A, Ea HK, Bazille C, et al. Osteoprotegerin inhibits cartilage degradation through an effect on trabecular bone in murine experimental osteoarthritis. Arthritis Rheum 2008;58:2379-2386.
23. Skoumal M, Kolarz G, Woloszczuk W, et al. Serum osteoprotegerin but not receptor activator of NF-κB ligand correlates with Larsen score in rheumatoid arthritis. Ann Rheum Dis 2004;63:216-217.
24. Pilichou A, Papassotiriou I, Michalakakou K, et al. High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis. Clin Biochem 2008;41:746-749.
25. Sambrook J, Fritsch EF, Maniatis T. Western blotting. In: Sambrook J, Fritsch EF, Maniatis T, eds. Molecular cloning: a laboratory manual. 2nd ed. Woodbury, NY: Cold Spring Harbor Laboratory Press, 1989;18.30-18.74.
26. Deschner J, Wypasek E, Ferretti M, et al. Regulation of RANKL by biomechanical loading in fibrochondrocytes of meniscus. J Biomech 2006;39:1796-1803.
27. Lambert C, Oury C, Dejardin E, et al. Further insights in the mechanisms of interleukin-1beta stimulation of osteoprotegerin in osteoblast-like cells. J Bone Miner Res 2007;22:1350-1361.
28. Komuro H, Olee T, Kühn K, et al. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. Arthritis Rheum 2001;44:2768-2776.
29. Nagasawa T, Kobayashi H, Kiji M, et al. LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. Clin Exp Immunol 2002;130:338-344.
30. Wada N, Maeda H, Yoshimine Y, et al. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factoralpha. Bone 2004;35:629-635.
31. Maruyama K, Takada Y, Ray N, et al. Receptor activator of NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice. J Immunol 2006;177:3799-3805.
32. Lu HK, Yeh KC, Wu MF, et al. An acute injection of Porphyromonas gingivalis lipopolysaccharide modulates the OPG/RANKL system and interleukin-6 in an ovariectomized mouse model. Oral Microbiol Immunol 2008;23:220-225.
33. Vidal NO, Brándström H, Jonsson KB, et al. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. J Endocrinol 1998;159:191-195.
34. Ishii T, Ohshima S, Ishida T, et al. Osteopontin as a positive regulator in the osteoclastogenesis of arthritis. Biochem Biophys Res Commun 2004;316:809-815.
35. Kondo T, Kitazawa R, Yamaguchi A, et al. Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels. J Cell Biochem 2008;103:335-345.
36. Zou W, Bar-Shavit Z. Dual modulation of osteoclast differentiation by lipopolysaccharide. J Bone Miner Res 2002;17:1211-1218.
37. Coon D, Gulati A, Cowan C, et al. The role of cyclooxygenase-2 (COX-2) in inflammatory bone resorption. J Endod 2007;33:432-436.
38. Tanaka H, Tanabe N, Shoji M, et al. Nicotine and lipopolysaccharide stimulate the formation of osteoclast-like cells by increasing macrophage colony-stimulating factor and prostaglandin E2 production by osteoblasts. Life Sci 2006;78:1733-1740.
39. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
40. Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997;234:137-142.
41. Haynes DR, Barg E, Crotti TN, et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology (Oxford) 2003;42:123-134.
42. Nakamura H, Tsuji T, Hirata A, et al. Localization of osteoprotegerin (OPG) on bone surfaces and cement lines in rat tibia. J Histochem Cytochem 2002;50:945-953.
43. Théoleyre S, Kwan Tat S, Vusio P, et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Biochem Biophys Res Commun 2006;347:460-467.
44. Hikita A, Yana I, Wakeyama H, et al. Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand. J Biol Chem 2006;281:36846-36855.
45. Hikita A, Kadono Y, Chikuda H, et al. Identification of an alternatively spliced variant of Ca2+-promoted Ras inactivator as a possible regulator of RANKL shedding. J Biol Chem 2005;280:41700-41706.